TrialJournal of hematology & oncology2022

Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.

Ke Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.